German Federal Government invests 300 Million Euros in CureVac
- Main shareholder dievini Hopp BioTech and the Federal Government agree on a landmark investment in a company in the innovative biotechnology sector for the first time
- Direct equity financing by the Federal Government is to be made by the Kreditanstalt für Wiederaufbau (KfW)
- mRNA company CureVac retains complete operational and strategic independence; the Federal Government will not influence corporate policy decisions
- It is a central step towards implementing the Corona Economic Stimulus and Future Technologies Package of the Federal Government from 03 June 2020
The German Federal Minister for Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and
co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG, announced today that the Federal Republic of Germany will invest 300 million Euros in
the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical development of mRNA-based drugs.The German Federal Minister for
Economic Affairs and Energy, Peter Altmaier, and Dietmar Hopp, SAP co-founder and
co-founder of the investment company dievini Hopp BioTech holding GmbH & Co. KG,
announced today that the Federal Republic of Germany will invest 300 million Euros in
the biopharmaceutical company CureVac AG, a pioneer in the preclinical and clinical
development of mRNA-based drugs.